Search research articles
Contact Us
Filters
Showing results (41-50 of 144) with videos related to
Page
of 15
Sort By:
Scientific Reports
|
July 25, 2020
<math> </math>: deep learning-based radiomics for the time-to-event outcome prediction in lung cancer
Parnian Afshar, Arash Mohammadi, Pascal N Tyrrell, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 28, 2006
Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy
Andrew Pearce, Richard Choo, Cyril Danjoux, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 23, 2016
Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials
H Bindu Musunuru, Harvey Quon, Melanie Davidson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 26, 2012
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy
Richard Choo, Himu Lukka, Patrick Cheung, et al.
Radiation Oncology (London, England)
|
April 24, 2015
Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer
William Chu, D Andrew Loblaw, Kelvin Chan, et al.
Annals of Palliative Medicine
|
August 14, 2020
A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions
George J Li, Andrew J Arifin, Faiez Al-Shafa, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 14, 2010
Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-term results
Hany Soliman, Patrick Cheung, Latifa Yeung, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 7, 2005
Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery
Sarat Chander, Richard Choo, Cyril Danjoux, et al.
The Canadian Journal of Urology
|
March 22, 2005
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Richard Choo, Sarat Chander, Cyril Danjoux, et al.
Frontiers in Oncology
|
September 14, 2016
Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials
Harvey C Quon, Hima Bindu Musunuru, Patrick Cheung, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 144) with videos related to
Sort By:
Page
of 15
Scientific Reports
|
July 25, 2020
<math> </math>: deep learning-based radiomics for the time-to-event outcome prediction in lung cancer
Parnian Afshar, Arash Mohammadi, Pascal N Tyrrell, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 28, 2006
Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy
Andrew Pearce, Richard Choo, Cyril Danjoux, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 23, 2016
Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials
H Bindu Musunuru, Harvey Quon, Melanie Davidson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 26, 2012
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy
Richard Choo, Himu Lukka, Patrick Cheung, et al.
Radiation Oncology (London, England)
|
April 24, 2015
Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer
William Chu, D Andrew Loblaw, Kelvin Chan, et al.
Annals of Palliative Medicine
|
August 14, 2020
A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions
George J Li, Andrew J Arifin, Faiez Al-Shafa, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 14, 2010
Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-term results
Hany Soliman, Patrick Cheung, Latifa Yeung, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 7, 2005
Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery
Sarat Chander, Richard Choo, Cyril Danjoux, et al.
The Canadian Journal of Urology
|
March 22, 2005
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Richard Choo, Sarat Chander, Cyril Danjoux, et al.
Frontiers in Oncology
|
September 14, 2016
Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials
Harvey C Quon, Hima Bindu Musunuru, Patrick Cheung, et al.
Page
of 15